P134 Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from two Phase 3 Studies
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.175
Abstract: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life; however, there are no accepted criteria for identifying axial involvement in PsA. The objective of this post-hoc analysis… read more here.
Keywords: novartis pfizer; investigator assessment; abbvie; axial involvement ... See more keywords
SAT0159 Impact of participation in the adalimumab patient support program on functional and clinical outcomes among patients with rheumatoid arthritis: passion study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1876
Abstract: Background Patients (pt) with Rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a Patient Support Program (PSP) with variety of services. To date, no prospective study has been conducted to analyze the… read more here.
Keywords: abbvie; psp non; study; non users ... See more keywords
FRI0188 Effectiveness of adalimumab combination therapy with methotrexate and non-methotrexate csdmards: results from the corrona rheumatoid arthritis registry
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1924
Abstract: Background Combination therapy of methotrexate (MTX) with biologics results in superior outcomes vs. monotherapy. However, little is known on the effectiveness of adalimumab (ADA) combination therapy with non-MTX conventional synthetic disease modifying anti-rheumatic drugs (csDMARD).… read more here.
Keywords: combination; abbvie; employee; corrona llc ... See more keywords
OP0243 Predictors of remission at week 12 in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab treatment in the ability-3 study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.6467
Abstract: Background Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) who fail nonsteroidal anti-inflammatory drug (NSAID) therapy are candidates for tumor necrosis factor inhibitor (TNFi) therapy if they have objective signs of inflammation. Baseline predictors of response… read more here.
Keywords: abbvie; pfizer; open label; ability ... See more keywords
SAT0254 Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from select-next
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1202
Abstract: Background: Upadacitinib (UPA), a selective JAK-1 inhibitor, has demonstrated efficacy in active RA among patients with an inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD-IR).1 To understand treatment effectiveness from the patients’ perspective we… read more here.
Keywords: employee abbvie; abbvie; shareholder abbvie; employee ... See more keywords
SAT0255 Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND PHASE III TRIAL)
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1254
Abstract: Background Patient reported outcomes (PROs) were studied in patients with active rheumatoid arthritis (RA) who had an inadequate response to biologic disease modifying anti-rheumatic drugs (bDMARD-IR) in a trial of upadacitinib (UPA), a selective JAK-1… read more here.
Keywords: employee abbvie; abbvie; shareholder abbvie; employee ... See more keywords
OP0334 Efficacy and safety of continuing versus withdrawing adalimumab (ADA) in maintaining remission in patients with non-radiographic axial spondyloarthritis (NR-AXSPA)
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2641
Abstract: Tapering and flaring in PsA and SpA Background It is not known whether TNF blockers can be stopped in nr-axSpA patients (pts) who are in remission. Objectives ABILITY-3, reported here, assessed if ADA can be… read more here.
Keywords: abbvie; ada; pbo; novartis pfizer ... See more keywords
SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2727
Abstract: Background Animal studies suggested that inhibiting IL-1α/β with lutikizumab (formerly, ABT-981) may reduce pain and slow structural progression in OA. Objectives This study (NCT02087904; ILLUSTRATE-K) assessed the safety and efficacy of lutikizumab in subjects with… read more here.
Keywords: employee; consultant abbvie; abbvie; shareholder abbvie ... See more keywords
SAT0576 Biomarkers predictive of pain improvement in knee osteoarthritis subjects treated with the anti-il-1 alpha/beta dual variable domain immunoglobulin lutikizumab (ABT-981)
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2730
Abstract: Background Development of disease-modifying drugs for OA has been challenging, partly due to lack of predictive biomarkers. Objectives Our primary objective was to identify baseline (BL) biomarkers predicting greater treatment effects on WOMAC pain among… read more here.
Keywords: shareholder abbvie; abbvie; employee; treatment ... See more keywords
THU0264 Impact of extra-articular manifestations on patient-reported outcomes in ankylosing spondylitis and psoriatic arthritis: interim results from the complete studies
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.3797
Abstract: Background Extra-articular manifestations (EAMs) in rheumatic diseases have been previously found to negatively impact health outcomes including quality of life and work capacity. Even though EAMs may be directly associated with worse response to treatment,… read more here.
Keywords: psa; abbvie; presence; disease ... See more keywords
OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4237
Abstract: Background Upadacitinib (UPA), an oral JAK inhibitor, showed efficacy in rheumatoid arthritis (RA) patients (pts) with an inadequate response to csDMARDs or bDMARDs on continuing stable csDMARD(s).1 2 Objectives Safety and efficacy of switching to… read more here.
Keywords: abbvie; inadequate response; ltd; mtx ... See more keywords